Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $829.45 million for fiscal year 2025.
ARROWHEAD PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $829.45M | +23258.2% |
| 2024 | $3.55M | -98.5% |
| 2023 | $240.74M | -1.0% |
| 2022 | $243.23M | +75.9% |
| 2021 | $138.29M | +57.2% |
| 2020 | $87.99M | -47.9% |
| 2019 | $168.80M | +945.7% |
| 2018 | $16.14M | -48.6% |
| 2017 | $31.41M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $264.03M | +10461.3% | +850.9% |
| June 30, 2025 | $27.77M | — | -94.9% |
| March 31, 2025 | $542.71M | — | +21608.4% |
| December 31, 2024 | $2.50M | -29.6% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| December 31, 2023 | $3.55M | -94.3% | -77.6% |
| June 30, 2023 | $15.82M | -51.2% | -89.2% |
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +23258.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, ARROWHEAD PHARMACEUTICALS, INC.’s revenue (asc 606) has grown by 2540.9% (from $31.41 million to $829.45 million).
- The most recent figure is from ARROWHEAD PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: